Bio-Path Holdings, Inc. (OTC BB: BPTH) (“Bio-Path”), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced financial and operational results for the year ended December 31, 2010.
2010 FINANCIAL AND OPERATIONAL HIGHLIGHTS
- Operational Highlights
- Enrollment continues in the Phase I clinical trial of its lead cancer drug product Liposomal Grb-2 (also “BP-100-1.01”). Through the end of the first quarter 2011, seven patients have been enrolled into the study, with another two additional patients in the process of being enrolled at the end of March 2011. Patients eligible for enrollment have refractory or relapsed Acute Myeloid Leukemia (AML), Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (CML) and Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) and who have failed other approved treatments. At the low initial dose levels in the clinical trial, it has taken longer than expected for the Principal Investigator to recruit patients into the trial. In addition, four of the initial patients were unable to stay on the entire four-week treatment cycle because of progressive disease, which was unrelated to treatment with Liposomal Grb-2, and consequently, had to be withdrawn from the study before completion of testing.It is important to note two of the three patients that completed the full four-week treatment cycle of the Phase I trial were placed on continuing treatment for additional cycles based on the Principal Investigator’s assessment that they were receiving benefit from the drug. Bio-Path’s FDA-approved protocol for the Phase I clinical trial provides that the Principal Investigator may continue treatment of a patient beyond the initial cycle if, in the Principal Investigator’s opinion the patient is exhibiting stable disease, or else, have improvement of their disease. In the circumstance where a patient is continuing treatment beyond the requirements of the Phase I trial, the Company is required to supply drug at no charge for the continuing treatments but does not incur additional hospital costs. Although it is too early to draw any scientific conclusions about any effect that the Company’s drug candidate Liposomal Grb-2 has on patients being treated in the trial, the effects of apparent stabilization in some patients is expected to help in recruiting new patients into the clinical trial. In this regard, the Company was very encouraged by the recent new enrollment of two new patients into the trial.
- It is now expected that an additional 12 months could be required to complete the Phase I clinical trial. We are seeking an additional 13-16 patients to complete the trial. Since, at the Principal Investigator’s recommendation, some patients who are benefiting from the treatment are being placed on continuing therapy beyond the requirements of the clinical trial, additional expenses may be incurred as the Company is required to supply drug at no charge for the continuing treatment. Additional costs to completion of the Phase I clinical trial are estimated to range from $750,000 to $1.2 million. Bio-Path believes it has sufficient resources and access to additional resources if needed to meet its obligations in this regard.
- The Company has raised approximately $1.4 million in connection with a planned private placement, with an amount in excess of $1 million already collected and the balance expected to be in escrow as of March 31, 2011.
- Financial Highlights
- Net loss for the year 2010 was $(2,081,500), compared to a Net Loss of $(1,969,738) for the year 2009. The increased Net Loss was due to an increase of $480,953 in research and development expenses related to the commencement in July of the Phase I clinical trial of Liposomal Grb-2. This was partially offset by a decline of $16,145 in general and administrative expense and a decline of $111,501 for 2010 in stock option expense in 2010. The Company also had Other Income of $244,479 representing a grant award from the U.S. Government. For the year 2010, the Company reported a net loss per share of $(0.04) based on 48,153,321 weighted average shares outstanding, compared to net loss per share of $(0.05) for the year 2009.
- Operating expenses for 2010 increased by 18 percent to $2,326,429 versus 2009 primarily due to increased research and development expenses for the clinical trial of Liposomal Grb-2.
- As of December 31, 2010, the Company had cash and grants receivable of $483,044 compared to $567,249 at December 31, 2009. The amount at December 31, 2010 is comprised of $238,565 in cash and a $244,479 grant receivable from the U.S. Government that was received in February 2011. Net cash used in operating activities for the year 2010 was reduced by $419,290, or 27 percent, compared to 2009. As previously stated, the Company has subsequently received, since the end of the fourth quarter, approximately $1 million from a private placement with another $400,000 committed and expected to be in escrow as of March 31, 2011.
Peter Nielsen, President and Chief Executive Officer of Bio-Path, commented, “2010 was an important year for Bio-Path Holdings. The Company commenced a Phase I clinical trial with its lead drug product candidate Liposomal Grb-2 for treatment of several blood cancers. While patient enrollment has been slower than expected at the early stage of the trial, which involves the lower dosages, we are very encouraged with some of the early results. In particular, we believe the effects of apparent stabilization in some patients from treatment with Liposomal Grb-2 could help in recruiting new patients into the clinical trial.”
Check Out Our Best Services for Investors
Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
Check Out Our Best Services for Investors
David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.